Richard Görlick
A5032743242- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Bone Tumor Diagnosis and Treatments
- CAR-T cell therapy research
- Virus-based gene therapy research
- RNA modifications and cancer
- Cancer therapeutics and mechanisms
- Cancer-related Molecular Pathways
- Molecular Biology Techniques and Applications
- Lymphoma Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- Acute Lymphoblastic Leukemia research
- RNA Research and Splicing
- Cancer, Hypoxia, and Metabolism
- Ubiquitin and proteasome pathways
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
Children's Hospital at Montefiore
2011-2024
Albert Einstein College of Medicine
2010-2024
The University of Texas MD Anderson Cancer Center
2017-2024
The University of Texas Health Science Center at Houston
2019-2023
Boston Children's Hospital
2008-2023
Montefiore Medical Center
2011-2021
Tulane University
2019
Children's Hospital of Philadelphia
2007-2018
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2018
Memorial Sloan Kettering Cancer Center
2001-2017
High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European American Osteosarcoma Study (EURAMOS)-1 collaboration of four study groups aiming to improve outcomes this rare disease by facilitating randomised controlled trials.Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade in which case complete surgical resection at all sites was deemed be possible. A three-drug combination methotrexate, doxorubicin...
Abstract Background The Pediatric Preclinical Testing Program (PPTP) is an initiative supported by the National Cancer Institute (NCI) to identify novel therapeutic agents that may have significant activity against childhood cancers. PPTP has established panels of cancer xenografts and cell lines be used for in vivo vitro testing. These include Wilms tumor, sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma), neuroblastoma, brain tumors (glioblastoma, ependymoma, medulloblastoma),...
We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response preoperative (≥10% viable tumour) improved event-free survival in with high-grade osteosarcoma.EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting newly diagnosed, resectable, osteosarcoma aged 40 years or younger were eligible randomisation. Patients randomly assigned (1:1) receive either cisplatin,...
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.
Four international study groups undertook a large in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based histological response.Patients with osteosarcoma aged ≤40 years were treated MAP regimen, comprising pre-operatively 5-week cycles cisplatin 120 mg/m(2), doxorubicin 75 methotrexate 12 g/m(2) × 2 (MAP) and post-operatively further just MA. Patients after surgery. Those ≥10% viable...
Abstract Osteosarcoma patient survival has remained stagnant for 30 years. Novel therapeutic approaches are needed to improve outcomes. We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined tumor immune microenvironment assess prognostic utility in osteosarcoma. PD-L1 osteosarcoma was two cohorts using immunohistochemistry (IHC) (n = 48, n 59) validated quantitative real time PCR 21) western blotting 9). IHC used determine presence infiltrating lymphocytes...
Despite efforts to intensify chemotherapy, survival for patients with metastatic osteosarcoma remains poor. Overexpression of human epidermal growth factor receptor 2 (HER2) in has been shown predict poor therapeutic response and decreased survival. This study tests the safety feasibility delivering biologically targeted therapy by combining trastuzumab standard chemotherapy HER2 overexpression.Among 96 evaluable newly diagnosed osteosarcoma, 41 had tumors that were HER2-positive...
<h3>Importance</h3> Osteosarcoma, the most common malignant bone tumor in children and adolescents, occurs a high number of cancer predisposition syndromes that are defined by highly penetrant germline mutations. The genetic susceptibility to osteosarcoma outside familial remains unclear. <h3>Objective</h3> To investigate architecture 1244 patients with osteosarcoma. <h3>Design, Setting, Participants</h3> Whole-exome sequencing (n = 1104) or targeted 140) DNA from 10 participating...
Abstract Limited clinical activity has been seen in osteosarcoma (OS) patients treated with immune checkpoint inhibitors (ICI). To gain insights into the immunogenic potential of these tumors, we conducted whole genome, RNA, and T-cell receptor sequencing, immunohistochemistry reverse phase protein array profiling (RPPA) on OS specimens from 48 pediatric adult primary, relapsed, metastatic OS. Median infiltrate level was lower than other tumor types where ICI are effective, concomitant low...
The use of radiographic response as the primary end point in phase II osteosarcoma trials may limit optimal detection treatment because calcified tumor matrix. We performed this study to determine if time progression could be used an for subsequent studies.We a retrospective analysis outcome patients with recurrent/refractory enrolled one seven conducted by Children's Oncology Group and predecessor groups from 1997 2007. All RECIST or WHO criteria rate. following potential prognostic...
Background The extracellular matrix (ECM) and cancer-associated fibroblasts (CAFs) play major roles in tumor progression, metastasis, the poor response of many solid tumors to immunotherapy. CAF-targeted chimeric antigen receptor-T cell therapy cannot infiltrate ECM-rich such as osteosarcoma. Method In this study, we used RNA sequencing assess whether recently invented membrane-anchored tumor-targeted IL-12-armed (attIL12) T cells, which bind cell-surface vimentin (CSV) on could destroy CAFs...
In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified. The aim of this study was to determine whether human epidermal growth factor receptor 2 (HER2)/erbB-2, p-glycoprotein, or p53 expression correlated with histologic response preoperative chemotherapy event-free survival.We performed a retrospective immunohistochemical on material obtained from patients treated the Memorial Sloan-Kettering Cancer Center T12 protocol between 1986 and...
PURPOSE It has been observed previously in osteosarcoma (OS) that the degree of necrosis resected primary tumor following a period preoperative chemotherapy is predictive subsequent event-free survival (EFS). The aim this study was to determine if more intensive would increase proportion patients with good histologic response and improve EFS. PATIENTS AND METHODS Seventy-three OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on T12 protocol between 1986 1993. Patients...